Market Overview

Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Acadia Pharmaceuticals Inc.

Share:

Robbins
Geller Rudman & Dowd LLP
(http://www.rgrdlaw.com/cases/acadiapharm/)
today announced that a class action has been commenced on behalf of
purchasers of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) securities
during the period between April 29, 2016 and July 9, 2018 (the "Class
Period"). This action was filed in the Southern District of California
and is captioned Stone v. ACADIA Pharmaceuticals Inc., et al.,
No. 18-cv-01672.

The Private Securities Litigation Reform Act of 1995 permits any
investor who purchased ACADIA securities during the Class Period to seek
appointment as lead plaintiff. A lead plaintiff acts on behalf of all
other class members in directing the litigation. The lead plaintiff can
select a law firm of its choice. An investor's ability to share in any
potential future recovery is not dependent upon serving as lead
plaintiff. If you wish to serve as lead plaintiff, you must move the
Court no later than 60 days from July 20, 2018. If you wish to discuss
this action or have any questions concerning this notice or your rights
or interests, please contact plaintiff's counsel, Darren
Robbins
of Robbins Geller at 800/449-4900 or 619/231-1058, or via
e-mail at djr@rgrdlaw.com. You can
view a copy of the complaint as filed at http://www.rgrdlaw.com/cases/acadiapharm/.

The complaint charges ACADIA and certain of its officers with violations
of the Securities Exchange Act of 1934. ACADIA is a biopharmaceutical
company focused on the development and commercialization of innovative
medicines to address unmet medical needs in central nervous system
disorders. ACADIA's product opportunities include its novel drug
NUPLAZID (pimavanserin), which was approved by the U.S. Food and Drug
Administration ("FDA") on April 29, 2016 for the treatment of
hallucinations and delusions associated with Parkinson's disease
psychosis. NUPLAZID became available in the United States in May 2016.

The complaint alleges that during the Class Period, defendants made
false and misleading statements and/or failed to disclose adverse
information regarding ACADIA's business and prospects, including that
medical professionals had expressed significant concern that NUPLAZID
had been approved too quickly, based on inadequate evidence that the
drug was safe or effective, and that a large number of adverse events
had been reported to the FDA for patients who were using NUPLAZID. As a
result of defendants' false statements and/or omissions, ACADIA
securities traded at artificially inflated prices during the Class
Period.

On April 9, 2018, CNN issued a report claiming that medical
professionals, including physicians, researchers and other experts, had
expressed significant concern that NUPLAZID was approved too quickly,
based on inadequate evidence that the drug was safe or effective. The
CNN report also called attention to a large number of adverse events
(often deaths) reported to the FDA for patients who were using NUPLAZID.
On this news, the Company's share price declined $5.03 per share, or
23.4%, to close at $16.50 per share on April 9, 2018. On April 25, 2018,
CNN reported that the FDA was re-examining the safety of NUPLAZID. On
this news, the Company's share price fell $4.27 per share, or 21.9%, to
close at $15.20 per share on April 25, 2018.

Then, on July 9, 2018, the Southern Investigative Reporting Foundation
issued a report, entitled "Acadia Pharmaceuticals: This Is Not a
Pharmaceuticals Company," alleging that ACADIA "has accomplished its
growth in ways that have attracted intense regulatory scrutiny for other
drug companies," including "dispensing wads of cash to doctors to
incentivize prescription writing and downplaying mounting reports of
patient deaths." On this news, the Company's share price again dropped
$1.21 per share, or 6.8%, to close at $16.63 per share on July 9, 2018.

Plaintiff seeks to recover damages on behalf of all purchasers of ACADIA
securities during the Class Period (the "Class").

Robbins Geller is one of the world's leading law firms representing
investors in securities litigation. With 200 lawyers in 10 offices,
Robbins Geller has obtained many of the largest securities class action
recoveries in history. For five consecutive years, ISS Securities Class
Action Services has ranked the Firm in its annual SCAS Top 50 Report as
one of the top law firms in both amount recovered for shareholders and
total number of class action settlements. Robbins Geller attorneys have
helped shape the securities laws and recovered tens of billions of
dollars on behalf of aggrieved victims. Beyond securing financial
recoveries for defrauded investors, Robbins Geller also specializes in
implementing corporate governance reforms, helping to improve the
financial markets for investors worldwide. Please visit http://www.rgrdlaw.com
for more information.

https://www.linkedin.com/company/rgrdlaw
https://twitter.com/rgrdlaw
https://www.facebook.com/rgrdlaw
https://plus.google.com/+Rgrdlaw/posts

View Comments and Join the Discussion!